94 related articles for article (PubMed ID: 20583137)
1. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
2. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
3. Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia.
Zhao Z; Zeng G
Endocr Relat Cancer; 2010 Jun; 17(2):505-12. PubMed ID: 20308359
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
[TBL] [Abstract][Full Text] [Related]
5. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
6. EPCA-2: a highly specific serum marker for prostate cancer.
Leman ES; Cannon GW; Trock BJ; Sokoll LJ; Chan DW; Mangold L; Partin AW; Getzenberg RH
Urology; 2007 Apr; 69(4):714-20. PubMed ID: 17445657
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
8. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
11. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
Bright EA; Manuel C; Goddard JC; Khan MA
Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
[TBL] [Abstract][Full Text] [Related]
12. Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.
Bales GT; Flynn TJ; Kynaston HG; Golash A; Hart A; Kim HL; Gerber GS
Tech Urol; 2000 Sep; 6(3):201-4. PubMed ID: 10963487
[TBL] [Abstract][Full Text] [Related]
13. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
14. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
15. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
[TBL] [Abstract][Full Text] [Related]
17. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
Chun FK; Müller I; Lange I; Friedrich MG; Erbersdobler A; Karakiewicz PI; Graefen M; Pantel K; Huland H; Schwarzenbach H
BJU Int; 2006 Sep; 98(3):544-8. PubMed ID: 16925751
[TBL] [Abstract][Full Text] [Related]
19. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
20. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
Ornstein DK; Rao GS; Smith DS; Andriole GL
J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
